Lamprecht Alf, Yamamoto Hiromitsu, Takeuchi Hirofumi, Kawashima Yoshiaki
Laboratory of Pharmaceutical Engineering, Pharmaceutical Engineering Department, Gifu Pharmaceutical University, 5-6-1 Mitahora Higashi, 502-8585, Japan.
J Control Release. 2004 Jul 23;98(1):1-9. doi: 10.1016/j.jconrel.2004.02.001.
Oral calcitonin (CT) administration is aimed in the treatment of calcemia in order to circumvent the required regular injections. CT containing microspheres (MS) were designed for colonic delivery by applying a pH-sensitive polymer Eudragit P-4135F for a double emulsion [water/oil/water (w/o/w)] microsphere preparation technique. CT was incorporated in the internal aqueous phase and carboxyfluorescein was encapsulated similarly to allow the characterization of the MS dissolution behavior. Eudragit P-4135F was found to keep the leakage of CT and carboxyfluorescein in vitro at pH 6.8 below 20% within 4 h while at pH 7.4, a fast release was observed for both, dye and peptide. Plasma levels of carboxyfluorescein after oral MS administration proved a sustained release in a rat model, where Cmax of carboxyfluorescein solution was found at around 60 min while for MS formulations it was detected after 4 h. At a dose of 20 microg CT/kg, no significant calcemic effects were found by MS formulations. However, increasing the dose to 100 microg CT/kg resulted in a distinct calcemia and revealed the sustained release properties of the MS. The relative pharmacological effect became most intense after 8-12 h based on the selective pH-dependent delivery. MS showed a fourfold increase of the area above the curve of calcium blood level compared to levels reached after CT solution. The coencapsulation of chitosan in the MS as absorption enhancer did not show any additional effect. The MS formulations proved their applicability as a promising device for pH-dependent colonic CT delivery and might be useful for other peptides.
口服降钙素(CT)旨在治疗血钙过多,以避免所需的定期注射。通过应用pH敏感聚合物Eudragit P-4135F进行双乳液[水/油/水(w/o/w)]微球制备技术,设计了含CT的微球(MS)用于结肠给药。CT被包封在内部水相中,羧基荧光素以类似方式包封,以表征MS的溶解行为。发现Eudragit P-4135F可使CT和羧基荧光素在体外pH 6.8时4小时内的泄漏率低于20%,而在pH 7.4时,染料和肽均出现快速释放。口服MS后羧基荧光素的血浆水平在大鼠模型中证明有持续释放,其中羧基荧光素溶液的Cmax在约60分钟时出现,而MS制剂在4小时后检测到。在20μg CT/kg的剂量下,MS制剂未发现明显的血钙影响。然而,将剂量增加到100μg CT/kg会导致明显的血钙过多,并揭示了MS的持续释放特性。基于选择性pH依赖性递送,相对药理作用在8-12小时后最为强烈。与CT溶液给药后达到的水平相比,MS显示血钙水平曲线以上的面积增加了四倍。在MS中共包封壳聚糖作为吸收增强剂未显示任何额外效果。MS制剂证明了其作为pH依赖性结肠CT递送的有前景装置的适用性,可能对其他肽也有用。